Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Medtech
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Evaluate Vantage Homepage
Pharmaceutical Companies
Bioven
February 27, 2017
Therapy focus – against the odds, cancer vaccines plough on
September 29, 2011
Therapeutic Focus - Diabetic foot ulcer market in need of healing
May 26, 2009
Therapeutic focus - cancer vaccines to come under scrutiny
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
January 20, 2022
JP Morgan 2022 Conference
January 11, 2022
PD(L)anner - December 2021
Editor's Picks
January 05, 2022
In 2021 it paid to stay private when the chips were down
January 07, 2022
Big beasts drive biopharma valuations higher in 2021
December 20, 2021
Another failure heaps more pressure on Novartis
January 04, 2022
Days of reckoning for immune checkpoint blockers
November 22, 2021
The bubble bursts for biotech stocks
